Table I.
Clinicopathological characteristics of the pre-operative TACE and non-TACE groups.
| Variable | Pre-operative TACE (n=252) | Non-TACE (n=243) | P-value |
|---|---|---|---|
| Age (years) | 60.9±8.4 | 62.2±8.8 | 0.107 |
| Gender (male/female) | 208/44 | 191/52 | 0.258 |
| HBs-Ag (+) | 108 | 96 | 0.404 |
| HCV-Ab (+) | 105 | 134 | 0.200 |
| Child-Pugh grade (A/B) | 217/35 | 207/36 | 0.404 |
| CLIP score (0/1-2/3-6) | 118/113/21 | 125/106/12 | 0.201 |
| Serum AFP (>5 ng/ml) | 78 | 72 | 0.845 |
| Serum PIVKA-II (>40 mAU/l) | 101 | 112 | 0.464 |
| Tumor size (cm) | 4.4±3.3 | 4.0±6.7 | 0.455 |
| Multiple tumors | 86 | 65 | 0.084 |
| Portal vein invasion (+) | 17 | 16 | 0.951 |
| Intrahepatic metastasis (+) | 74 | 46 | <0.010 |
| TNM stage (I/II/III/IV-A) | 47/135/55/15 | 53/130/41/19 | 0.465 |
TACE, transcatheter arterial embolization; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K antigen II. Data are expressed as the mean ± SD.